CoreMap has secured $37 million in an oversubscribed Series C financing round led by Medtronic, strengthening its position in the rapidly evolving cardiac care market and providing fresh capital to advance its next-generation atrial fibrillation mapping technology. The investment highlights growing industry confidence in technologies designed to improve the precision of catheter ablation procedures and address one of the most common heart rhythm disorders worldwide.
The latest funding round, which also included participation from existing and new investors, nearly doubles the total capital raised by the Massachusetts-based company since its establishment in 2016. CoreMap plans to use the proceeds to accelerate product development, expand clinical validation efforts, and support commercialization activities for its advanced electrophysiology platform.
The announcement comes at a time when cardiovascular disease remains one of the leading causes of mortality globally, while atrial fibrillation continues to place a significant burden on healthcare systems. Increasing demand for more personalized and data-driven cardiac interventions has created new opportunities for companies developing advanced mapping technologies that can improve procedural outcomes.
CoreMap’s work also reflects broader trends in the market for electrophysiology devices, where physicians are seeking tools capable of delivering more detailed information about abnormal electrical activity in the heart. As hospitals and specialty cardiac centers adopt increasingly sophisticated treatment approaches, advanced mapping systems are becoming a critical component of modern electrophysiology procedures.
Industry analysts note that investments in cardiac technologies have accelerated over the past several years, driven by rising patient volumes, growing awareness of minimally invasive treatments, and continuous innovation in imaging, mapping, and ablation systems.
Demand Grows for More Precise Atrial Fibrillation Treatment
Atrial fibrillation, often referred to as AF, affects millions of people globally and is associated with increased risks of stroke, heart failure, and other cardiovascular complications. The condition occurs when irregular electrical signals disrupt the heart’s normal rhythm, making effective diagnosis and treatment a major focus for cardiologists and electrophysiologists.
Catheter ablation has emerged as an important treatment option for patients with persistent or difficult-to-control atrial fibrillation. However, treatment success often depends on the physician’s ability to accurately identify the sources of abnormal electrical activity within the heart.
CoreMap aims to address this challenge through a high-density mapping system that combines proprietary sensing technology with advanced analytical capabilities. The company’s platform is designed to generate real-time, three-dimensional maps of the heart’s electrical activity, allowing physicians to better understand patient-specific arrhythmia patterns.
By offering a more detailed visualization of electrical signals, the system could help clinicians perform more targeted ablation procedures while reducing unnecessary tissue damage. Improved precision may lead to better outcomes, shorter procedures, and potentially lower rates of repeat interventions.
Sarah Kalil, Chief Executive Officer of CoreMap, said the financing provides the company with resources to move its platform closer to broader clinical adoption.
According to Kalil, the goal is to equip electrophysiologists with better information so they can deliver more personalized treatment strategies for patients with atrial fibrillation.
Healthcare providers are increasingly recognizing that no two AF patients present exactly the same disease patterns. As a result, technologies that support individualized treatment planning are gaining significant attention across the cardiovascular sector.
The growing interest in patient-specific therapies has also driven investment in digital cardiac technologies, including advanced imaging, predictive analytics, and mapping systems that can improve procedural decision-making.
Medtronic Strengthens Position in Expanding Electrophysiology Market
For Medtronic, the investment in CoreMap represents another strategic step in expanding its presence within the fast-growing electrophysiology market.
The global electrophysiology sector has attracted significant attention in recent years due to rising demand for minimally invasive procedures and new technologies that improve the treatment of complex arrhythmias. Market research firms estimate that the electrophysiology devices market could reach nearly $25 billion by 2035, supported by continued innovation in mapping systems, ablation technologies, and cardiac imaging tools.
Although Medtronic faces strong competition from established players such as Biosense Webster and Boston Scientific, the company has gained momentum through its pulsed-field ablation portfolio and broader cardiovascular business.
Medtronic’s cardiac ablation segment has recorded strong growth in recent quarters, driven largely by increasing adoption of next-generation ablation technologies. The addition of advanced mapping capabilities through strategic investments such as CoreMap could further strengthen the company’s long-term position.
Industry observers suggest that future success in electrophysiology will depend not only on the effectiveness of ablation devices but also on the quality of mapping technologies that guide procedures.
The collaboration between established medical technology companies and emerging innovators is becoming increasingly common as firms seek to build integrated solutions for physicians. Rather than focusing on individual products, companies are creating ecosystems that combine mapping, imaging, analytics, and treatment platforms.
For CoreMap, the new financing provides an opportunity to accelerate its technology roadmap and bring its atrial fibrillation mapping platform to a broader clinical audience. For Medtronic, the investment reinforces its commitment to advancing cardiac care through innovation.
As the prevalence of atrial fibrillation continues to rise globally, technologies that improve diagnosis, procedural precision, and long-term patient outcomes are expected to remain a major area of investment across the medical device industry.
Ref: https://med-tech.world/news/coremap-medtronic-37m-funding-round/
